



Universiteit
Leiden
The Netherlands

HNPCC, molecular and clinical dilemmas

Wagner, A.

Citation

Wagner, A. (2005, April 27). *HNPCC, molecular and clinical dilemmas*. Macula, Boskoop.
Retrieved from <https://hdl.handle.net/1887/2719>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/2719>

Note: To cite this publication please use the final published version (if applicable).

3.1.

**Atypical HNPCC owing to *MSH6* germline mutations;
analysis of a large Dutch pedigree**

J Med Genet 2001;38;318-322

Shortreport

Atypical HNPCC owing to *MSH6* germline mutations: analysis of a large Dutch pedigree

Department of Clinical Genetics, Erasmus University Rotterdam, The Netherlands

A Wagner
EJ Meijers-Heijboer
C van der Meer
D Lindhout
MF Niermeijer

Department of Human and Clinical Genetics, Leiden University Medical Centre, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands

A Wagner
Y Hendriks
CTops
EBik
AHJT Bröcker-Vriends
MHBreuning
AHZwinderman
JWijnen
RFodde

Department of Pathology, Leiden University Medical Centre, The Netherlands
WJF de Leeuw
H Morreau
CJ Cornelisse

Department of Medical Genetics, University Hospital Groningen, The Netherlands
RHofstra

Department of Medical Genetics, University Medical Centre Utrecht, The Netherlands
DLindhout

The Netherlands Foundation for the Detection of Hereditary Tumours, The Netherlands
HFAV asen

Department of Pathology, Reinier de Graaf Gasthuis/SSIZ, Delft, The Netherlands
C van Krimpen

Correspondence to:
Dr Fodde,
R.Fodde@LUMC.nl

Revised version received
25 January 2001
Accepted for publication 15
February 2001

A Wagner, Y Hendriks, EJ Meijers-Heijboer, WJF de Leeuw, H Morreau, RHofstra, CTops, EBik, AHJT Bröcker-Vriends, C van der Meer, DLindhout, HFAV asen, MHBreuning, CJ Cornelisse, C van Krimpen, MF Niermeijer, AHZwinderman, JWijnen, RFodde

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) is the most common genetic susceptibility syndrome for colorectal cancer. HNPCC is most frequently caused by germline mutations in the DNA mismatch repair (MMR) genes *MSH2* and *MLH1*. Recently, mutations in another MMR gene, *MSH6* (also known as *GTBP*), have also been shown to result in HNPCC. Preliminary data indicate that the phenotype related to *MSH6* mutations may differ from the classical HNPCC caused by defects in *MSH2* and *MLH1*.

Here, we describe an extended Dutch HNPCC family not fulfilling the Amsterdam criteria II and resulting from a *MSH6* mutation. Overall, the penetrance of colorectal cancer appears to be significantly decreased ($p < 0.001$) among the *MSH6* mutation carriers in this family when compared with *MSH2* and *MLH1* carriers (32% by the age of 80 v >80%).

Endometrial cancer is a frequent manifestation among female carriers (six out of 13 malignant tumours). Transitional cell carcinoma of the urinary tract is also relatively common in both male and female carriers (10% of the carriers).

Moreover, the mean age of onset of both colorectal cancer (*MSH6* v *MSH2/MLH1* = 55 years v 44/41 years) and endometrial carcinomas (*MSH6* v *MSH2/MLH1* = 55 years v 49/48 years) is delayed. As previously reported, we confirm that the pattern of microsatellite instability, in combination with immunohistochemical analysis, can predict the presence of a *MSH6* germline defect.

The detailed characterisation of the clinical phenotype of this kindred contributes to the establishment of genotype-phenotype correlations in HNPCC owing to mutations in specific mismatch repair genes.

(J Med Genet 2001;38:318–322)

Keywords: hereditary non-polyposis colorectal cancer; *MSH6*

Hereditary non-polyposis colorectal cancer (HNPCC) is one of the most common autosomal dominant conditions predisposing to cancer. HNPCC carriers are at risk for the development of a broad spectrum of malignancies including tumours of the colon, endometrium, stomach, small intestine, hepatobiliary system, ureter, renal pelvis, and ovary.¹ HNPCC is caused by germline mutations in DNA mismatch repair (MMR) genes, predominantly *MSH2* on chromosome 2p16² and *MLH1* on chromosome 3p21.³ In a minority of cases, mutations have been described in other MMR genes like *PMS1* and *PMS2*.⁴ Recently, germline mutations in the *MSH6* gene on chromosome 2p15 were recognised as a frequent cause of atypical HNPCC, that is, not complying with the clinical "Amsterdam criteria".^{5–9}

The involvement of MMR genes in HNPCC is reflected by the occurrence of instability of simple repetitive DNA sequences (microsatellite instability or MSI) in tumours from HNPCC patients. Accordingly, more than 90% of the colorectal tumours and at least 75% of the endometrial tumours from HNPCC patients display MSI.^{10–12} In sporadic colorectal and endometrial cancer, MSI is found in about 15–30% of tumours.^{13,14}

The first report on *MSH6* germline mutations has indicated that the clinical phenotype of the affected families may differ from the "classical" HNPCC caused by *MSH2* and *MLH1* mutations.^{5–9} The penetrance of colorectal cancer seemed to be reduced. However, endometrial cancer was likely to represent a more important clinical manifestation among female *MSH6* carriers. The reported mean age of onset of colorectal and endometrial cancer appeared to be delayed in families with *MSH6* germline mutations, 50 years and older compared to 44 (*MSH2*) and 41 (*MLH1*) years of age¹⁵ and 53 years and older compared to 49 (*MSH2*) and 48 (*MLH1*) years, respectively.⁷ Notably, MSI analysis of tumours from *MSH6* mutation carriers suggested a reduced penetrance of the MSI-H phenotype and preferential instability at mononucleotide repeats.^{7–9,12}

Here, we report the clinical and molecular characterisation of a large HNPCC kindred




Figure 1 Pedigree of MSH6 family. C=colorectal cancer. E=endometrial cancer. U=urinary tract cancer. P=polyp. O=ovarian cancer. B=breast cancer. Br=brain tumour. Ca?=cancer of unknown origin. +=MSH6 mutation positive. -=MSH6 mutation negative.

resulting from a frameshift mutation in the MSH6 gene.

Patients

The proband, a 50-year-old female, was referred to the Department of Clinical Genetics,

Rotterdam by her gynaecologist in 1993. At that time, three of her six sisters were diagnosed with endometrial cancer at 50, 57, and 60 years of age. A fourth sister had developed ovarian cancer (endometrioid adenocarcinoma) at the age of 50. The proband's father died at the age of 85 without any symptoms of HNPCC. Her mother underwent a hysterectomy for leiomyomata at 55 and was in good health at 92 years of age.

The differential diagnosis in this family included HNPCC. Mutation analysis of the *MLH1* and *MSH2* genes by PCR and DGGE in one of the affected sisters of the proband did not show any pathogenic mutation. In the meantime, the proband developed endometrial cancer at the age of 53, the fourth case of endometrial cancer in this sibship.

As soon as *MSH6* mutation analysis became available, mutation screening was performed and a frameshift mutation (delT codon 594) in exon 4 was identified. The proband, her affected sisters, and mother were found to carry the same mutation.

At the request of the proband, family members were informed about the findings and were invited to contact the Department of Clinical Genetics for additional information and/or to be tested for the presence of the mutation.

We were also able to link the family to another kindred under investigation at the Department of Clinical Genetics at the Leiden University Medical Centre.

Mutation analysis

In total, DNA testing for the *MSH6* mutation was performed in 80 out of 132 living relatives with at least a 25% risk of being carrier of the *MSH6* mutation (fig 1), 27 males (out of 63, 43%) and 53 females (out of 69, 77%). Out of these 132 relatives, 11 were previously diagnosed with an HNPCC-related tumour and all of them were retested. Two tested and affected relatives were obligate carriers. Out of 75 carriers at 50% risk and 44 at 25% risk, 46 (61%) and 21 (48%) were retested, respectively (tables 1 and 2).

Ten of the 11 affected subjects were carriers of the familial *MSH6* mutation. The patient (IV.6) negative for the mutation was a 55-year-old male, diagnosed with numerous tubulovillous adenomas at the age of 53. Since his clinical presentation was suggestive of familial adenomatous polyposis (FAP), though with a delayed age of onset, mutation analysis of the *APC* gene was performed. This did not show any alteration.

The *MSH6* mutation was confirmed in both unaffected obligate carriers.

Out of the 46 tested healthy subjects with a 50% risk for the mutation, 17 (37%) were found to carry the *MSH6* mutation; none of those with a 25% risk tested positive (table 2).

All 11 unaffected mutation carriers above the age of 25 years (five males and 12 females) were offered the generally accepted surveillance for HNPCC, namely colonoscopy every one to two years, yearly gynaecological examination with vaginal ultrasound and CA125 blood testing

Table 1 (Pre) malignant tumours in the extended Dutch MSH6 family

Patient Tumour	Age at diagnosis MSH6 mutation
II.2 Colorectal cancer	60 Obligate carrier
III.2 Transitional cell carcinoma right pyelum 77 Obligate carrier & transitional cell carcinoma left ureter 79	
III.4 Transitional cell carcinoma	78+
III.6 Unknown	40 Not tested
III.11 Endometrial carcinoma	50 Obligate carrier
Colon carcinoma	>70
III.13 Colon carcinoma	>70 Not tested
III.18 Colon carcinoma	83+
III.19 Astrocytoma	75 Not tested
IV.4 Transitional cell carcinoma ureter	59+
IV.6 Multiple adenomatous polyps of the colon 53-	
IV.8 Adenoma	50+
IV.9 Adenoma	48+
IV.11 Tubulovillous adenoma	60+
IV.13 Endometrial & rectal carcinoma	55+
IV.14 Breast cancer	51 Not tested
IV.15 Breast & colon carcinoma	49+
IV.20 Breast cancer	>50 Not tested
IV.26 Endometrial carcinoma	57+
IV.27 Endometrial carcinoma	60+
IV.30 Endometrioid adenocarcinoma ovary	50+
IV.32 Endometrial carcinoma	53+
IV.33 Endometrial carcinoma	50+
V.8 Colorectal cancer	32+

+ indicates the presence of the MSH6 mutation.
- indicates the absence of the MSH6 mutation.

Table 2 Result of mutation analysis

	Male	Female	Total
Pretest risk 100%*50%25%100%*50%25%			
Tested	5157	8311480	
MSH6+	440	813029	
MSH6-	1117	0181451	
Not tested 01917		010652	
Total	53424	84120132	

*Relatives with an HNPCC related tumour and obligate carriers.

(for female carriers), and yearly urinesediment testing and cytology. During the first screening the following diagnoses were made: a tubulovillous adenoma with dysplasia in the proximal rectum of a 60 year old male; an invasive ductal adenocarcinoma of the breast and an adenocarcinoma of the colon in a 49 year old female; a small tubular adenoma and endometrial hyperplasia in a 50 year old female; and an adenoma in a female aged 48. Of the remaining 13 carriers, four were under the age of 45 and four were above 70 years without any symptoms of the genetic predisposition. However, a 92 year old female underwent a hysterectomy because of leiomyomata of the uterus at the age of 55.

Table 3 Microsatellite and immunohistochemical analysis in tumours from 12 affected relatives

	Subject	III.2	III.4	III.13	III.18	IV.4	IV.6	IV.13	IV.15	IV.26	IV.27	IV.30	IV.32
Tumour type	UUUCCUPRECBEEOE												
Microsatellite status	HHLNTHHLSHLSHHLHS												
Mononucleotide markers													
BAT25*	+++NT+---+---+---+												
BAT26*	NT+---NT												
BAT40	+++NT+++/-+---NT+++												
Dinucleotide markers													
D2S123*	+NT-NT--NT												
D5S346*	-+NT+---+-----												
D17S250*	+NT-NT												
Immunohistochemistry													
MLH1	NTNT++++NT+++++++												
MSH2	NTNT++++NT+-----												
MSH6	NTNT+---NT+-----NT-												

*=markers recommended by NCI for MSI analysis. ¹⁶ +=Unstable, -=Stable. NT=not tested/not conclusive. H=MSI high according to NCI recommendations. ¹⁶ L=MSI low according to NCI recommendations. ¹⁶ S=MSI stable according to NCI recommendations. ¹⁶ C=colontumour. U=urinary tract tumour. E=endometrial tumour. O=ovarian tumour. R=rectal tumour. P=polyp. B=breast tumour. Immunohistochemistry: +++=strong staining, ++=moderate staining, +=weak staining, -=no staining.

The family included five dead obligate mutation carriers, three females and two males. Three of them had been diagnosed with a HNPCC related tumour (table 1). One male reached the age of 83 without having developed any HNPCC related tumour.

We were not able to determine the MSH6 status of five cancer patients in this family: one colorectal cancer (onset >70) in a female patient (III.13) whose 13 descendant tested negative for the mutation; one male with an astrocytoma (III.19) at the age of 75, three of whose four children did not carry the mutation; two breast cancer patients (IV.14, IV.20, onset >50); and one patient with cancer of unknown origin around the age of 40 (III.6).

In total, 34 mutation carriers (29 alive and five dead) were identified in this pedigree, 17 of whom developed a (pre) malignant tumour (table 1). Of the carriers with a malignancy, four had two primary HNPCC related tumours. Using the Kaplan-Meier method, 7% of the carriers developed colorectal cancer by the age of 50 years and 32% by the age of 80 years (mean age of onset 55 years, ranging from 32 to 83 years). Of the female carriers, 52% developed endometrial cancer by the age of 80 and all of them were diagnosed above the age of 50 years. Three carriers had a papillary transitional cell carcinoma of the urinary tract (10% of the carriers).

Microsatellite instability (MSI) and immunohistochemical (IHC) analyses

We performed MSI analysis and/or immunohistochemistry with antibodies against MLH1, MSH2, and MSH6 ¹² on tumour samples derived from 12 subjects; in four cases, two independent tumour samples were tested (table 3).

Using the markers recommended by Boland *et al*, ¹⁶ MSI analysis showed variable patterns (table 3). However, all tumour samples derived from the MSH6 carriers displayed instability of at least one mononucleotide marker when an extended set of markers, including BAT40, was used.

Immunohistochemical (IHC) analysis of the MSH6 protein in tumour sections showed no expression in any of the samples tested, with

the exception of III.13 and IV.6. Patient III.13 could not be tested for either the presence of the germline mutation or for MSI, and is likely to represent a phenocopy, in view of the late age of onset (colon carcinoma at >70 years) and the failure to detect the *MSH6* mutation in her 13 descendants. We were able to perform MSI analysis in a single adenoma from patient IV.6 that did not display instability for any of the tested markers. *MLH1* and *MSH2* IHC analysis was positive in all samples with the exception of the rectal carcinoma from IV.13, negative for *MSH2*.

Discussion

Genetic heterogeneity and variable phenotypic expression represent major complications in the diagnosis and clinical management of HNPCC, one of the most common inherited predisposition to multiorgan tumorigenesis. Although the hallmark of this condition is represented by colorectal lesions, a broad range of cancer types, including tumours of the endometrium, stomach, small intestine, hepatobiliary system, and ureter, are established clinical expressions of HNPCC. The vast majority of HNPCC cases are known to result from germline mutations in the DNA mismatch repair genes *MSH2* and *MLH1*.¹⁷ In these kindreds, high penetrance and early onset of colorectal and endometrial cancer are the major clinical features. These of diagnostic criteria, Amsterdam criteria I and II, established by the International Collaborative Group on HNPCC^{18,19} well serve the purpose of selecting families with a high likelihood of carrying *MSH2* and *MLH1* mutations.¹⁷ More recently, atypical HNPCC families, that is, not complying with the Amsterdam criteria (ACI and II) though clearly suggestive of a HNPCC-like inherited condition, have been reported to be caused by germline mutations in a third MMR gene, namely *MSH6*.⁷⁻⁹ Preliminary phenotypic analysis of these families showed a reduced occurrence of colorectal cancer and a prevalence of endometrial tumours.

Here, we have presented a detailed analysis of an extended Dutch HNPCC pedigree resulting from an inactivating germline mutation of the *MSH6* gene.

The expression of the *MSH6* mutation in this family suggests a reduced penetrance and a delayed age of onset for colorectal cancer. Using the Kaplan-Meier method, 7% of the carriers developed colorectal cancer by the age of 50 years and 32% by the age of 80 years. This is significantly reduced ($p < 0.001$) compared to "classical" HNPCC caused by *MSH2* and *MLH1* (~55% by age 50 and >80% by age 80).¹⁵ Admittedly, these calculations are based on a limited number of cases and may represent an overestimate because not all healthy eligible relatives were tested for the *MSH6* mutation. Moreover, the selection bias introduced when studying a family with such a striking clinical history may also lead to an overestimation of the penetrance. The mean age of onset of the colorectal carcinomas in this family is 55 years. This is delayed when

compared with HNPCC families caused by *MSH2* (44 years) and *MLH1* (41 years) mutations.¹⁵ This delayed age of onset may also bias the estimated penetrance. Notably, the youngest diagnosed case was at 32 years, implying that periodic screening recommendations should not differ from those established for classical HNPCC until more data are available.

In this family, endometrial cancer is the most common tumour type (six out of 13 malignant tumours) among female carriers. All the endometrial cancers were diagnosed above the age of 50 and their mean age of onset was 55 years, that is, five to 10 years later when compared with "classical" HNPCC caused by mutations in *MLH1* and *MSH2*.^{7,20}

Another striking clinical phenotype in this family is the papillary transitional cell carcinoma of the ureter and renal pelvis observed in three relatives (10% of the carriers). Notably, the lifetime cumulative risk of this tumour type in *MLH1* or *MSH2* mutation carriers is only 2.6%.²¹

As previously reported by us and others,⁷⁻⁹ the MSI phenotype caused by loss of *MSH6* function is reduced when compared with *MLH1* and *MSH2*, and differs in its predominance at mononucleotide runs. This is in agreement with previous studies on yeast and mouse model systems.^{22,23} From this point of view, the set of markers previously recommended by NCI for MSI analysis¹⁶ may not be suitable for *MSH6* mutation carriers and should be complemented with a set of mononucleotide markers. In six of the cases reported here (III.4, IV.4U, IV.13E, IV.15C, IV.27, and IV.32) (table 3), instability was observed at only one or two mononucleotide repeats (one of which was not included in the NCI panel) leading to an MSI-low or stable classification. In five of these cases, IHC was performed and indicated the loss of *MSH6* in the tumour. Therefore, we recommend IHC analysis in MSI-L and MSS tumours from cases with a family history suggestive of HNPCC.¹²

We also show the feasibility of the IHC approach not only on colorectal tumours but also in carcinoma of the endometrium, urinary tract, and breast. The latter finding is relevant for the inclusion of breast cancer in the HNPCC tumours spectrum: breast tumour samples from IV.15 showed both MSI-high and a negative IHC staining pattern in accordance with the presence of the *MSH6* germline mutation in this person. Two additional perimenopausal breast cancer cases were found in the present study (IV.14 and IV.20). However, as no material was available from these patients, we could not establish their *MSH6* mutation carrier status.

IHC analysis was also helpful in the assessment of the likely phenocopy status relative to III.13. As a limited amount of colorectal carcinoma was available from this dead patient, we limited our analysis to IHC and found normal *MSH6* protein expression. Moreover, all her descendants tested negative for the mutation. Another dead patient from

this family, III.19, was diagnosed with astrocytoma at the age of 75. Again, no archival material was available from this patient. However, the delayed age of onset and the fact that three of his children tested negative for the mutation, do not allow us to draw any conclusion on the relationship between the presence of the brain tumour and the *MSH6* defect.

Patient IV.6 presented with a clinical phenotype more suggestive of attenuated polyposis rather than HNPCC. Accordingly, MSI analysis of the colonic polyps was negative (MSS) and normal *MSH6* expression was found by IHC. Failure to detect the *MSH6* mutation in this patient confirmed that the attenuated polyposis is likely to result from an unlinked genetic predisposition.

In conclusion, the clinical features associated with *MSH6* germline mutations strongly support the inclusion of endometrial cancer and transitional cell cancer of the ureter and renal pelvis in the diagnostic criteria for HNPCC in the new Amsterdam Criteria (ACI) as formulated by the ICG-HNPCC.¹⁹ In addition, we propose to perform MSI in combination with IHC in all Amsterdam negative families with a clustering of endometrial or urinary tract cancers. The combined MSI and IHC analysis will direct subsequent mutation analysis for *MSH6*.

We thank Dr JJPMP ieters, gynaecologist, for referring the family to the Department of Clinical Genetics, Rotterdam.

- 1 Lynch HT, dela Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. *J Med Genet* 1999;36:801-18.
- 2 Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog *MSH2* and its association with hereditary nonpolyposis colorectal cancer. *Cell* 1993;75:1027-38.
- 3 Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergård P, Bollag RJ, Godwin AR, Ward DC, Nordenskjöld M, Fishel R, Kolodner R, Liskay RM. Mutation in the DNA mismatch repair gene homolog *hMLH1* is associated with hereditary non-polyposis colorectal cancer. *Nature* 1994;368:258-61.
- 4 Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Malcolm GD, Hamilton SR, Petersen GM, Chapelle A, Vogelstein B, Kinzler KW. Mutation of two PMS homologues in hereditary nonpolyposis colorectal cancer. *Nature* 1994;371:75-80.
- 5 Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, Yuasa Y. Germ-line mutation of the *MSH6*/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. *Cancer Res* 1997;57:3920-3.
- 6 Miyaki M, Konishi M, Tanaka K, Kikuchi Y, Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of *MSH6* as the cause of hereditary nonpolyposis colorectal cancer. *Nat Genet* 1997;17:271-2.
- 7 Wijnen J, de Leeuw W, Vasen H, van der Klift H, Moller P, Stormorken A, Meijers-Heijboer H, Lindhout D, Menko F, Vossen S, Moslein G, Tops C, Brocker-Vriends A, Wu Y, Hofstra R, Simjans R, Cornelisse C, Morreau H, Fodde R. Familial endometrial cancer in female carriers of *MSH6* germline mutations. *Nat Genet* 1999;23:142-4.
- 8 Wu Y, Berends MJ, Mensink RG, Kempinga C, Simjans RH, van der Zee AG, Hollema H, Kleibouker JH, Buys CH, Hofstra RM. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with *MSH6* germline mutations. *Am J Hum Genet* 1999;65:1291-8.
- 9 Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, Wahlberg S, Fox EA, Peel D, Ziogas A, Garber JE, Syngal S, Anton-Culver H, Li FP. Germ-line *msb6* mutations in colorectal cancer families. *Cancer Res* 1999;59:5068-74.
- 10 Fujiwara T, Stalker JM, Watanabe T, Rashid A, Longo P, Eshleman JR, Booker S, Lynch HT, Jass JR, Green JS, Kim H, Jen J, Vogelstein B, Hamilton SR. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. *Am J Pathol* 1998;153:1063-78.
- 11 Ichikawa Y, Lemon SJ, Wang S, Franklin B, Watson P, Knezetic JA, Bewtra C, Lynch HT. Microsatellite instability and expression of *MLH1* and *MSH2* in normal and malignant endometrial and ovarian epithelium in hereditary nonpolyposis colorectal cancer family members. *Cancer Genet Cytogenet* 1999;112:2-8.
- 12 de Leeuw WJ, Dierssen J, Vasen HF, Wijnen JT, Kenter GG, Meijers-Heijboer H, Brocker-Vriends A, Stormorken A, Moller P, Menko F, Cornelisse CJ, Morreau H. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. *J Pathol* 2000;192:328-35.
- 13 Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature* 1993;363:558-61.
- 14 Helland A, Borresen-Dale AL, Peltomäki P, Hektoen M, Kristensen GB, Nesland JM, dela Chapelle A, Lothe RA. Microsatellite instability in cervical and endometrial carcinomas. *Int J Cancer* 1997;70:499-501.
- 15 Vasen HF, Wijnen JT, Menko FH, Kleibouker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Berti L, Varesco L, Bisgaard ML, Mohr J, Fodde R, Khan PM. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis (published erratum appears in *Gastroenterology* 1996;111:1402). *Gastroenterology* 1996;110:1020-7.
- 16 Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248-57.
- 17 Wijnen JT, Vasen HF, Khan PM, Zwiderman AH, van der Klift H, Mulder A, Tops C, Moller P, Fodde R. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. *Engl J Med* 1998;339:511-18.
- 18 Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). *Dis Colon Rectum* 1991;34:424-5.
- 19 Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. *Gastroenterology* 1999;116:1453-6.
- 20 Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. *Am J Med* 1994;96:516-20.
- 21 Simjans RH, Kiemeneij LA, Witjes JA, Vasen HF. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. *J Urol* 1998;160:466-70.
- 22 Alani E. The Saccharomyces cerevisiae Msh2 and Msh6 proteins form a complex that specifically binds to duplex oligonucleotides containing mismatched DNA base pairs. *Mol Cell Biol* 1996;16:5604-15.
- 23 Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan K, Liedtke W, Cohen PE, Kane MF, Lipford JR, Yu N, Crouse GF, Pollard JW, Kunkel T, Lipkin M, Kolodner R, Kucherlapati R. Mutation in the mismatch repair gene *Msh6* causes cancer susceptibility. *Cell* 1997;91:467-77.
- 24 Leppert M, Burt R, Hughes JP, Samowitz W, Nakamura Y, Woodward S, Gardner E, Lalouel JM, White R. Genetic analysis of an inherited predisposition to colon cancer in a family with a variable number of adenomatous polyps. *Engl J Med* 1990;322:904-8.

